Niagen Bioscience, Inc. (NAGE) stock analysis
Consumer Defensive · Packaged Foods
From the 10-K filed 2026-03-04
How it makes money
It earns by selling NAD+ precursor ingredients and finished supplements, with consumer demand and marketing efficiency as the primary drivers of profit.
The company monetizes proprietary vitamin B3 ingredients through its direct-to-consumer brand, Tru Niagen, and through supply agreements with compounding pharmacies and FDA-registered facilities. Profitability depends on its ability to maintain high consumer interest in healthy aging and the cost-effectiveness of its advertising campaigns.
What protects it: the moat
It relies on a portfolio of owned and licensed patents to defend its proprietary NAD+ technology from competitors.
The company asserts that its market position is secured through its research-backed intellectual property and collaborations with academic institutions. However, management admits that it is uncertain whether these protections are sufficient to prevent challenges or infringements that could harm its market share.
What growth costs
It incurs significant costs from marketing and must settle royalty or acquisition obligations to secure its core intellectual property.
The company spends heavily on marketing to capture consumers and must manage the costs associated with its research collaborations and patent acquisitions. It recently settled royalty obligations and acquired full patent rights to reduce ongoing costs.
What could damage it
It relies on a single supplier for its primary ingredient, meaning a production failure would instantly halt its ability to sell its core products.
The company depends entirely on W.R. Grace to manufacture its proprietary NRC ingredient. If this sole supplier experiences operational issues, the company lacks an immediate alternative to maintain its supply chain, resulting in a total loss of product revenue.
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.